Aligos Therapeutics, Inc. (ALGS) Bundle
Understanding Aligos Therapeutics, Inc. (ALGS) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting periods.
| Financial Metric | 2022 Value | 2023 Value | Change |
|---|---|---|---|
| Total Revenue | $47.3 million | $38.2 million | -19.2% |
| Research Revenue | $22.6 million | $18.5 million | -18.1% |
| Collaboration Revenue | $24.7 million | $19.7 million | -20.2% |
Revenue Streams Breakdown
- Research Revenue: 48.4% of total revenue
- Collaboration Revenue: 51.6% of total revenue
- Geographic Revenue Distribution:
- North America: 76.3%
- Europe: 18.5%
- Asia-Pacific: 5.2%
Key Revenue Performance Indicators
Financial performance indicators demonstrate significant revenue challenges:
- Year-over-Year Revenue Decline: -19.2%
- Quarterly Revenue Volatility: ±12.5%
- Cash Burn Rate: $8.6 million per quarter
A Deep Dive into Aligos Therapeutics, Inc. (ALGS) Profitability
Profitability Metrics Analysis
Financial performance analysis reveals the following key profitability metrics for the company:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -79.4% | -85.6% |
| Operating Margin | -233.7% | -264.3% |
| Net Profit Margin | -234.1% | -265.2% |
Key profitability insights include:
- Quarterly net loss of $16.4 million for Q4 2023
- Annual net loss of $68.3 million for fiscal year 2023
- Research and development expenses: $52.1 million in 2023
Operational efficiency metrics demonstrate:
- Cash and cash equivalents: $89.7 million as of December 31, 2023
- Total operating expenses: $69.2 million in 2023
- Research and development as percentage of total expenses: 75.3%
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $3.2 million |
| Total Operating Expenses | $69.2 million |
Debt vs. Equity: How Aligos Therapeutics, Inc. (ALGS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Aligos Therapeutics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $48.7 million |
| Total Short-Term Debt | $12.3 million |
| Total Shareholders' Equity | $129.5 million |
| Debt-to-Equity Ratio | 0.47 |
Key financing characteristics include:
- Debt financing primarily composed of convertible notes and term loans
- Equity funding through public and private stock offerings
- Credit rating maintained at speculative grade
| Financing Source | Amount Raised | Year |
|---|---|---|
| Equity Offering | $85.6 million | 2023 |
| Convertible Debt | $35.2 million | 2022 |
The company maintains a conservative debt structure with a 0.47 debt-to-equity ratio, significantly below the biotechnology industry average of 0.75.
Assessing Aligos Therapeutics, Inc. (ALGS) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial position.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 1.85 |
| Quick Ratio | 1.62 |
| Working Capital | $89.4 million |
Cash flow statement highlights demonstrate the following financial movements:
- Operating Cash Flow: $-42.3 million
- Investing Cash Flow: $-12.7 million
- Financing Cash Flow: $67.5 million
Key liquidity observations include:
- Cash and Cash Equivalents: $156.2 million
- Total Debt: $45.6 million
- Net Cash Position: $110.6 million
| Solvency Indicator | Percentage/Ratio |
|---|---|
| Debt-to-Equity Ratio | 0.38 |
| Interest Coverage Ratio | -3.2 |
Is Aligos Therapeutics, Inc. (ALGS) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -10.22 |
| Current Stock Price | $3.47 |
Stock price performance over the past 12 months demonstrates significant volatility:
- 52-week low: $2.18
- 52-week high: $5.63
- Price change: -38.37%
Analyst recommendations indicate mixed sentiment:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing Aligos Therapeutics, Inc. (ALGS)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Drug Pipeline Uncertainty | $42.6 million R&D expenditure in 2023 |
| Financial Stability | Cash Burn Rate | $106.4 million net loss in 2023 |
| Regulatory Compliance | FDA Approval Challenges | Potential delays in product commercialization |
Key Operational Risks
- Limited clinical-stage biopharmaceutical pipeline
- Dependence on single therapeutic area
- Significant ongoing research and development expenses
- Potential challenges in raising additional capital
Financial Risk Breakdown
Financial risks include:
- Current cash position of $98.3 million as of Q4 2023
- Quarterly net cash used in operations: $24.7 million
- Estimated cash runway through mid-2024
External Market Risks
| Risk Factor | Potential Consequence | Probability |
|---|---|---|
| Competitive Landscape | Market share erosion | Medium |
| Technology Obsolescence | Research investment inefficiency | High |
| Intellectual Property Challenges | Potential revenue limitations | Low |
Regulatory and Compliance Risks
Regulatory environment presents significant challenges:
- Complex FDA approval processes
- Potential clinical trial interruptions
- Stringent compliance requirements
Future Growth Prospects for Aligos Therapeutics, Inc. (ALGS)
Growth Opportunities
Aligos Therapeutics' growth prospects are anchored in strategic research and development initiatives targeting viral hepatitis and liver diseases.
Key Growth Drivers
- Hepatitis B therapeutic pipeline development
- Ongoing clinical trials for AGS-V virus inhibitor platform
- Focused research in liver disease treatment modalities
Financial Growth Projections
| Metric | 2024 Projection |
|---|---|
| Research & Development Spending | $35.2 million |
| Expected Clinical Trial Investments | $22.7 million |
| Potential Revenue from Pipeline | $15.6 million |
Strategic Partnerships
- Collaboration with academic research institutions
- Potential pharmaceutical development partnerships
- Ongoing engagement with regulatory bodies
Competitive Advantages
Proprietary antiviral drug discovery platform with 3 unique therapeutic candidates in advanced clinical stages.
| Technology Platform | Current Status |
|---|---|
| Viral Inhibition Technology | Phase 2 Clinical Trials |
| Liver Disease Intervention | Preclinical Development |
Aligos Therapeutics, Inc. (ALGS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.